The global subcutaneous immunoglobulins market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of primary immunodeficiency and secondary immunodeficiency across the globe. The subcutaneous immunoglobulins market in North America is expected to grow at a CAGR of 6.2% during the forecast period, from 2021 to 2030. This growth can be attributed to factors such as increasing awareness about primary and secondary immunodeficiencies among healthcare professionals and patients, rising incidence rates for these diseases in North America, and growing number of clinical trials for subcutaneous immunoglobulins in North America.
The global subcutaneous immunoglobulins market by type (10% purity, 20% purity) is projected to grow at a CAGR of 4.8%, from 2021-2030 due to increasing demand for 10% purity products over 20% purity products due their lower cost per unit volume as well as their ease-of-use with respect to administration technique which makes them more suitable for children or elderly patients who are unable or unwilling/unable due difficulty with injection technique or fear associated with needles/injections respectively; however, there are some disadvantages associated with 10% purity products such as increased risk of adverse reactions like anaphylaxis which may lead physicians not prescribing them on account thereof; also there are some advantages associated with 10% purity products such as they have been shown in clinical trials that they have similar efficacy when compared against higher concentrations (20%) but without any increase in adverse events which may make them more attractive than higher concentration preparations.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of chronic diseases such as cancer and diabetes is driving the growth of the global Subcutaneous Immunoglobulins market.
- Increasing awareness about immunoglobulin therapy among patients and physicians is also driving the growth of the global Subcutaneous Immunoglobulins market.
- The increasing number of clinical trials for immunoglobulin therapy in various indications such as cancer, autoimmune disorders, and infectious diseases are also driving the growth of this market.
- The high cost associated with immunoglobulin therapy is a major restraint for this market.
Industry Growth Insights published a new data on “Subcutaneous Immunoglobulins Market”. The research report is titled “Subcutaneous Immunoglobulins Market research by Types (10% Purity, 20% Purity), By Applications (Primary Immunodeficiency, Secondary Immunodeficiency, Others), By Players/Companies Shire (Baxalta), Grifols, CSL”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Subcutaneous Immunoglobulins Market Research Report
By Type
10% Purity, 20% Purity
By Application
Primary Immunodeficiency, Secondary Immunodeficiency, Others
By Companies
Shire (Baxalta), Grifols, CSL
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Subcutaneous Immunoglobulins Market Report Segments:
The global Subcutaneous Immunoglobulins market is segmented on the basis of:
Types
10% Purity, 20% Purity
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Primary Immunodeficiency, Secondary Immunodeficiency, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Shire (Baxalta)
- Grifols
- CSL
Highlights of The Subcutaneous Immunoglobulins Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 10% Purity
- 20% Purity
- By Application:
- Primary Immunodeficiency
- Secondary Immunodeficiency
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Subcutaneous Immunoglobulins Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Subcutaneous immunoglobulins are a type of antibody that is injected directly into the skin. They help protect the body from infection by providing immunity to specific antigens.
Some of the major players in the subcutaneous immunoglobulins market are Shire (Baxalta), Grifols, CSL.
The subcutaneous immunoglobulins market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Subcutaneous Immunoglobulins Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Subcutaneous Immunoglobulins Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Subcutaneous Immunoglobulins Market - Supply Chain
4.5. Global Subcutaneous Immunoglobulins Market Forecast
4.5.1. Subcutaneous Immunoglobulins Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Subcutaneous Immunoglobulins Market Size (000 Units) and Y-o-Y Growth
4.5.3. Subcutaneous Immunoglobulins Market Absolute $ Opportunity
5. Global Subcutaneous Immunoglobulins Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Subcutaneous Immunoglobulins Market Size and Volume Forecast by Type
5.3.1. 10% Purity
5.3.2. 20% Purity
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Subcutaneous Immunoglobulins Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Subcutaneous Immunoglobulins Market Size and Volume Forecast by Application
6.3.1. Primary Immunodeficiency
6.3.2. Secondary Immunodeficiency
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Subcutaneous Immunoglobulins Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Subcutaneous Immunoglobulins Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Subcutaneous Immunoglobulins Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Subcutaneous Immunoglobulins Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Subcutaneous Immunoglobulins Demand Share Forecast, 2019-2026
9. North America Subcutaneous Immunoglobulins Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Subcutaneous Immunoglobulins Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Subcutaneous Immunoglobulins Market Size and Volume Forecast by Application
9.4.1. Primary Immunodeficiency
9.4.2. Secondary Immunodeficiency
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Subcutaneous Immunoglobulins Market Size and Volume Forecast by Type
9.7.1. 10% Purity
9.7.2. 20% Purity
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Subcutaneous Immunoglobulins Demand Share Forecast, 2019-2026
10. Latin America Subcutaneous Immunoglobulins Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Subcutaneous Immunoglobulins Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Subcutaneous Immunoglobulins Market Size and Volume Forecast by Application
10.4.1. Primary Immunodeficiency
10.4.2. Secondary Immunodeficiency
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Subcutaneous Immunoglobulins Market Size and Volume Forecast by Type
10.7.1. 10% Purity
10.7.2. 20% Purity
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Subcutaneous Immunoglobulins Demand Share Forecast, 2019-2026
11. Europe Subcutaneous Immunoglobulins Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Subcutaneous Immunoglobulins Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Subcutaneous Immunoglobulins Market Size and Volume Forecast by Application
11.4.1. Primary Immunodeficiency
11.4.2. Secondary Immunodeficiency
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Subcutaneous Immunoglobulins Market Size and Volume Forecast by Type
11.7.1. 10% Purity
11.7.2. 20% Purity
11.8 Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Subcutaneous Immunoglobulins Demand Share, 2019-2026
12. Asia Pacific Subcutaneous Immunoglobulins Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Subcutaneous Immunoglobulins Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Subcutaneous Immunoglobulins Market Size and Volume Forecast by Application
12.4.1. Primary Immunodeficiency
12.4.2. Secondary Immunodeficiency
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Subcutaneous Immunoglobulins Market Size and Volume Forecast by Type
12.7.1. 10% Purity
12.7.2. 20% Purity
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Subcutaneous Immunoglobulins Demand Share, 2019-2026
13. Middle East & Africa Subcutaneous Immunoglobulins Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Subcutaneous Immunoglobulins Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Subcutaneous Immunoglobulins Market Size and Volume Forecast by Application
13.4.1. Primary Immunodeficiency
13.4.2. Secondary Immunodeficiency
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Subcutaneous Immunoglobulins Market Size and Volume Forecast by Type
13.7.1. 10% Purity
13.7.2. 20% Purity
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Subcutaneous Immunoglobulins Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Subcutaneous Immunoglobulins Market: Market Share Analysis
14.2. Subcutaneous Immunoglobulins Distributors and Customers
14.3. Subcutaneous Immunoglobulins Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Shire (Baxalta)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Grifols
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CSL
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
